Glycogen Synthase Kinase‐3β as a Central Regulator of Alzheimer's Disease: Mechanistic Insights and Therapeutic Perspectives
European Journal of Neuroscience · 2026-11 · 64 (9)
DOI: 10.1111/ejn.70741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neuroscience, online erschienen am 06.11.2026. Verfasst von Sumaiya Kifayat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Glycogen Synthase Kinase 3 beta. Die Arbeit nennt 123 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurological condition marked by cognitive decline, memory impairment, extracellular amyloid‐β (Aβ) accumulation, and intracellular neurofibrillary tangles (NFTs). Among the multiple molecular pathways involved in AD pathogenesis, glycogen synthase kinase‐3β (GSK‐3β) has emerged as a crucial signaling regulator due to its extensive contribution to neuronal survival, synaptic plasticity, metabolism, and cellular stress responses. Growing evidence suggests that abnormal activation of GSK‐3β contributes not merely to classical AD hallmarks, including tau hyperphosphorylation and amyloidogenesis, but is also linked to mitochondrial dysfunction, neuroinflammation, autophagic impairment, ferroptosis, insulin resistance, and oxidative stress through modulation of the Nrf2 pathway. These findings place GSK‐3β as a crucial molecular hub linking different pathogenic pathways in AD. This review outlines the structural attributes along with regulatory mechanisms of GSK‐3β and extensively explores its involvement in AD pathophysiology. Specific emphasis is given to evolving mechanisms, such as metabolic dysregulation, ferroptosis, and antioxidant signaling pathways. Additionally, current breakthroughs in therapeutic targeting techniques such as ATP‐competitive inhibitors, non–ATP‐competitive inhibitors, allosteric modulators, natural chemicals, and clinically studied medicines are emphasized. The translational difficulties linked to selectivity, blood–brain barrier permeability, and clinical efficacies are also explored. Collectively, this review reinforces the therapeutic relevance of GSK‐3β and indicates potential opportunities for creating effective disease‐modifying therapies in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- Department of Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India.
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
ORCID-Profile: Sumaiya Kifayat, Wasim Kifayat, Saurabh Kumar Chauhan, Areesh Zehra, Abul Kalam Najmi, Suhel Parvez, Mohd Akhtar
Zitieren
APA
Kifayat, S., Kifayat, W., Chauhan, S. K., Zehra, A., Kaushik, R., Najmi, A. K., Parvez, S., Ali, J., & Akhtar, M. (2026). Glycogen Synthase Kinase‐3β as a Central Regulator of Alzheimer's Disease: Mechanistic Insights and Therapeutic Perspectives. European Journal of Neuroscience, 64(9). https://doi.org/10.1111/ejn.70741
Vancouver
Kifayat S, Kifayat W, Chauhan SK, Zehra A, Kaushik R, Najmi AK, et al. Glycogen Synthase Kinase‐3β as a Central Regulator of Alzheimer's Disease: Mechanistic Insights and Therapeutic Perspectives. European Journal of Neuroscience. 2026;64(9). doi:10.1111/ejn.70741
BibTeX
@article{Kifayat2026,
author = {Kifayat, Sumaiya and Kifayat, Wasim and Chauhan, Saurabh Kumar and Zehra, Areesh and Kaushik, Renu and Najmi, Abul Kalam and Parvez, Suhel and Ali, Javed and Akhtar, Mohd},
title = {Glycogen Synthase Kinase‐3β as a Central Regulator of Alzheimer's Disease: Mechanistic Insights and Therapeutic Perspectives},
journal = {European Journal of Neuroscience},
year = {2026},
volume = {64},
number = {9},
doi = {10.1111/ejn.70741}
}
EUVIMED